Clinical trials: IBD - Inflammatory Bowel Disease
Crohns Disease
Treatment of Moderate to Severe Refractory Crohn's Disease
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD).
- Trial name
- NCT06721962
- Testing
- TRX103, Cyclophosphamide
- Where
- 13 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tr1X, Inc.
Rheumatoid Arthritis, Crohn's Disease
The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and…
- Conditions
- Rheumatoid Arthritis, Crohn's Disease, Ankylosing Spondylitis, Psoriasis
- Trial name
- NCT00224562
- Testing
- TNF-alpha antagonists
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Inflammatory Bowel Diseases, Children, Only
Hyperbaric Oxygen Therapy in Children With Inflammatory Bowel Diseases
The study assesses the effectiveness of hyperbaric oxygen therapy in the treatment of inflammatory bowel disease in children.
- Trial name
- NCT03576027
- Testing
- Hyperbaric Oxygen Therapy
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Medical University of Warsaw
MASH, PSC
A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.
The goal of this clinical trial is to use positron emission tomography (PET) to evaluate and compare the binding of the novel tracer [68Ga]Ga-DOTA-Cys-ATH001 in the liver and/or gastrointestinal tract between healthy volunteers…
- Conditions
- MASH, PSC, Fibrostenotic Crohn's Disease, Healthy Volunteers
- Trial name
- NCT06562361
- Testing
- [68Ga]Ga-DOTA-Cys-ATH001
- Where
- 3 sites in Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Antaros Medical
Colitis, Ulcerative
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.
- Trial name
- COLLECT (NCT01493960)
- Testing
- Cobitolimod
- Where
- 37 sites in Czechia, France and 5 more
- Volunteers
- 131 people
- Sponsor
- InDex Pharmaceuticals
Crohn Disease
A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease
Psychological intervention by COBMINDEX application to reduce psychological stress among CD patients, fatigue and pain and improve the patients' well being, quality-of-life and disease-coping skills, as well as improvement of the…
- Trial name
- COBMINDEX (NCT06221254)
- Testing
- COBMINDEX digital application, Human therapist (Control)
- Where
- 4 sites in Israel
- Volunteers
- 200 people
- Sponsor
- Soroka University Medical Center
Ulcerative Colitis (UC), Crohn Disease (CD)
Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study
This clinical study protocol aims to prospectively compare the efficacy of standard therapy with anti-TNF agents combined with the Crohn's Disease Exclusion Diet (CDED) versus anti-TNF therapy alone in adult patients with active…
- Trial name
- IDEA-TNF (NCT06896305)
- Testing
- CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapy, Anti-TNF Therapy
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Ospedale San Raffaele
Crohn's Disease
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study is to evaluate the efficacy of abrilumab as measured by the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission (CDAI < 150) after treatment for 8 weeks.
- Trial name
- NCT01696396
- Testing
- Abrilumab
- Where
- 84 sites in United States, Austria and 10 more
- Volunteers
- 254 people
- Sponsor
- Amgen
Inflammatory Bowel Diseases, Ileostomy
Malnutrition Associated With Complications After Ileostomy Reversal
An ileostomy is a surgical opening established by bringing the end or a loop of the ileum to discharge directly outside the body.
- Trial name
- NCT03909542
- Where
- United States
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Crohn's Disease
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with…
- Trial name
- NCT00358683
- Testing
- Certolizumab pegol
- Sponsor
- UCB Pharma
Crohn's Disease
The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)
Crohn's disease(CD) is a agnogenic disease which has a lifelong relapse tendency even after surgery treatment.So maintain remission medications were routinely given to patients after surgery.But maintain remission medications,as…
- Trial name
- NCT01823042
- Testing
- azathioprine+enteral nutrition, Azathioprine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinling Hospital, China
Crohn's Disease, Inflammatory Bowel Diseases
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's…
- Trial name
- FUN-CD (NCT06274554)
- Testing
- Fluconazole, IL-23 Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Weill Medical College of Cornell University
Crohn's Disease (CD)
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients…
- Trial name
- COMANDOR (NCT07078994)
- Testing
- anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose
- Where
- 20 sites in Russia
- Volunteers
- 204 people
- Sponsor
- Biocad
Crohn Disease
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
The purpose of study is to test the effect of an experimental medication GED-0301(mongersen) and evaluate its safety in patients (≥ 12 years of age) with active Crohn's disease.
- Trial name
- NCT02974322
- Testing
- GED-0301
- Where
- 311 sites in United States, Australia and 28 more
- Sponsor
- Celgene
Irritable Bowel Syndrome, Metabolic Syndrome
Evaluation of Dietary Supplementation in Patients With Gastrointestinal Disorders.
The term "inflammaging" describes the aging process characterized by a chronic low-grade inflammatory state. With advancing age, this condition is often associated with cardiovascular disease, diabetes, and neurodegenerative…
- Trial name
- TrioB (NCT06960941)
- Testing
- TrioBiotix360®, Booklet with a series of postural hygiene exercises
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ulcerative Colitis
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ELEVATE UC 12 (NCT03996369)
- Testing
- Etrasimod
- Where
- 407 sites in United States, Argentina and 39 more
- Volunteers
- 354 people
- Sponsor
- Arena Pharmaceuticals
Ulcerative Colitis
A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants
The primary purpose of this study is to evaluate the safety and tolerability of H021 tablets following oral administration of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06627556
- Testing
- H021
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Ulcerative Colitis
Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
The overarching goal of this study, is to create a longitudinally followed, well phenotyped cohort of patients with UC starting treatment with tofacitinib in the setting of standard of care who have linked clinical data and…
- Trial name
- TOUR (NCT03772145)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of North Carolina, Chapel Hill
Irritable Bowel Syndrome, Inflammatory Bowel Diseases
A Personalized Approach to Abdominal Pain in Irritable Bowel Syndrome
Apart from its use to provide insight in IBS disease courses and in clinical research, ESM can provide patients with feedback about individual triggers of their symptoms, and thereby function as part of a personalized therapeutic…
- Conditions
- Irritable Bowel Syndrome, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- PERCEPTIvE (NCT05998577)
- Testing
- ESM and Traqq
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Maastricht University Medical Center
Crohn Disease (CD)
HB-adMSCs for the Treatment of Crohn's Disease
Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post…
- Trial name
- NCT07077746
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Hope Biosciences Research Foundation